← Leaderboards
Katherine Beebe Devarney
Titan Pharmaceuticals, Inc.
$27,187,371
Attributed
$27,187,371
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $6.1M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,187,371 · 4
By mechanism
UG3$8,741,592 · 1
RC2$7,586,848 · 1
U01$7,405,564 · 1
UH3$3,453,367 · 1
Top collaborators
No co-investigators on record.
Most similar at Titan Pharmaceuticals, Inc.
Same institution · by research overlap
- Rajesh A Patel$3,697,500
- Sunil P Sreedharan$247,500
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsDoseImplantSafetyCessation Of LifeInjectionsReportingRelapseSubcutaneousBasePlasmaDrug KineticsFormulationImplantationProgramsClinical ResearchTabletsCompliance BehaviorEffective TherapyOpioidHalf-LifeOralPlacebosEthylenes
Grant awards (7)
Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD).$3,274,441
U01 · FY2025 · DA · contact PI
Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD).$4,131,123
U01 · FY2024 · DA · contact PI
Development of a 3-month implantable depot pellet of Naltrexone for the treatment of Opioid Use Disorder.$3,453,367
UH3 · FY2021 · DA · contact PI
Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder$6,075,000
UG3 · FY2019 · DA · contact PI
Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder$2,666,592
UG3 · FY2018 · DA · contact PI
A Six-Month, RCT of Probuphine Safety and Efficacy in Opioid Addiction$2,022,838
RC2 · FY2010 · DA · contact PI
A Six-Month, RCT of Probuphine Safety and Efficacy in Opioid Addiction$5,564,010
RC2 · FY2009 · DA · contact PI